Epigenomics AG / Key word(s): Study/Miscellaneous 17.12.2014 / 11:00 Berlin (Germany) and Germantown, MD (U.S.A.), December 17, 2014 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), the German-American cancer molecular diagnostics company, today announced that first patients have been enrolled into its ADMIT trial (ADherence to Minimally Invasive Testing) for its noninvasive blood-based test […]
Category: Press Releases
17. December 2014
Epigenomics AG: First Patients Enrolled in Epigenomics’ Epi proColon(R) ADMIT Study
Read more
10. December 2014
Epigenomics AG: Epigenomics to present at the Oppenheimer 25th Annual Healthcare Conference
Epigenomics AG / Key word(s): Conference 10.12.2014 / 09:30 Epigenomics to present at the Oppenheimer 25th Annual Healthcare Conference Berlin (Germany) and Germantown, MD (U.S.A.), December 10, 2014 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), the German-American cancer molecular diagnostics company, today announced that CEO/CFO Dr. Thomas Taapken will be presenting at the […]
08. December 2014
Epigenomics AG: Epigenomics and BioChain Announce Approval of Epi proColon(R) in China
Epigenomics AG / Key word(s): Regulatory Approval 08.12.2014 / 08:05 Epigenomics and BioChain Announce Approval of Epi proColon(R) in China Berlin (Germany), Germantown, MD, and Newark, CA (U.S.A.) and Beijing (China), December 08, 2014 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), the German-American cancer molecular diagnostics company, and BioChain, a leading clinical diagnostics […]
11. November 2014
Epigenomics AG: Epigenomics AG Announces 2014 Third Quarter and Nine Month Financial Results and Reports on Operational Highlights
Epigenomics AG / Key word(s): 9-month figures 11.11.2014 / 08:30 Epigenomics AG Announces 2014 Third Quarter and Nine Month Financial Results and Reports on Operational Highlights Berlin (Germany) and Germantown, MD (U.S.A.), November 11, 2014 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), the German-American cancer molecular diagnostics company, today announced its financial results […]
03. November 2014
Epigenomics AG: Epigenomics’ strategic commercialization partner Polymedco reiterates its commitment to support Epi proColon(R) in the United States
Epigenomics AG / Key word(s): Alliance 03.11.2014 / 10:34 Epigenomics’ strategic commercialization partner Polymedco reiterates its commitment to support Epi proColon(R) in the United States Berlin (Germany) and Germantown, MD (USA), November 03, 2014 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), the German-American cancer molecular diagnostics company, today announced that Polymedco, Inc., a […]
27. October 2014
Epigenomics AG: Results of Adherence Study Published in BMC Gastroenterology Demonstrate that Epigenomics’ Blood-based Epi proColon(R) Improves Compliance to CRC Screening
Epigenomics AG / Key word(s): Scientific publication 27.10.2014 / 08:30 Results of Adherence Study Published in BMC Gastroenterology Demonstrate that Epigenomics’ Blood-based Epi proColon(R) Improves Compliance to CRC Screening Berlin (Germany) and Germantown, MD (U.S.A), October 27, 2014 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), the German-American cancer molecular diagnostics company, today announced […]